SCHEMBL515782

SCHEMBL515782

NOC(=O)CCCCCCC(=O)ON

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.42
TSHR P16473 3/20 0.41
LMNA P02545 6/20 0.40
NFKB1 P19838 1/20 0.40
PMP22 Q01453 1/20 0.40
PAM P19021 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
PLG P00747 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
SLC6A2 P23975 1/20 0.38
RECQL P46063 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 1/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 1/20 0.37
PAOX Q6QHF9 1/20 0.36
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065353 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27738121 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27672248 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL9593894 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL1064431 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL2180897 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27705302 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL9593713 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27569510 0.97 DGKA (0.41) DGKATSHRLMNANFKB1PMP22
SCHEMBL28175756 0.97 DGKA (0.41) DGKATSHRLMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046947-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2023-02-16 US claimed
EP-4069311-A1 REACTIVE CONJUGATES Debiopharm Research & Manufacturing SA (CH) 2022-10-12 EP claimed
WO-2021110860-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2021-06-10 WO claimed
CN-103429269-B Contain with the coupling of polyanion polypeptide, derived from the conjugated molecule that is used for the treatment of AIDS of the peptide of CD4 acceptor INSTITUT PASTEUR (FR) 2016-05-11 CN claimed
CN-103429269-A New conjugated molecules comprising peptide derived from CD4 receptor coupled to polyanionic polypeptide for treatment of AIDS PASTEUR INSTITUT 2013-12-04 CN claimed
CN-103119208-A A biocidal polyolefin yarn with 3-12 filaments VESTERGAARD FRANDSEN SA 2013-05-22 CN claimed
CN-101580546-A Human anti human interferon alpha antibody and application thereof INST OF VIRUS DISEASE CONTROL (CN) 2009-11-18 CN claimed
CN-101168514-A Practical synthesis method for alpha-aminosuberate and alpha-amino suberic acid monoester with optical activity SHANGHAI PHARMATECH CO LTD (CN) 2008-04-30 CN claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed
CN-118369123-A Tetrazine conjugates for in vivo targeted delivery of payloads 坦博公司 2024-07-19 CN disclosed
CN-117801204-A Bio-based hydrolysis-resistant elastomer, preparation method and application thereof 万华化学集团股份有限公司 2024-04-02 CN disclosed
WO-2023150684-A2 NANOMATERIAL AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2023-08-10 WO disclosed
US-20230046947-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2023-02-16 US disclosed
CN-115279416-A Reactive conjugates 德彪药业国际股份公司 2022-11-01 CN disclosed
EP-0408371-A1 Hemoregulatory peptides SMITHKLINE BEECHAM CORPORATION (US) 1991-01-16 EP disclosed
CN-87100308-A Polypeptide compound 1987-09-16 CN disclosed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN disclosed
US-4248786-A Hydroxy-succinimide ester compounds BOEHRINGER MANNHEIM GMBH (DE) 1981-02-03 US disclosed
US-4155914-A Hydroxy-succinimide ester compounds BOEHRINGER MANNHEIM GMBH (DE) 1979-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046947-A1 REACTIVE CONJUGATES FCGR3B, FCGR1A, FCGR2A DGKA 3400/4885TSHR 510/4885LMNA 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.